Carcinoma in Situ of the Bladder

• FDA approval · 2019-04-19
  FDA Approved: VALRUBICIN INTRAVESICAL SOLUTION — Original Application (Hikma Pharmaceuticals USA Inc.)

  FDA approved Hikma's generic valrubicin intravesical solution (ANDA 206430) for carcinoma in situ of the bladder in patients who have failed…

• FDA approval · 2013-11-12
  FDA Approved: VALSTAR — Supplemental Application (Endo USA, Inc.)

  The FDA approved a supplemental application for VALSTAR (valrubicin) submitted by Endo USA, Inc.

• FDA approval · 2012-12-20
  FDA Approved: VALSTAR — Supplemental Application (Endo USA, Inc.)

  FDA approved a supplemental application for VALSTAR (valrubicin) from Endo USA, Inc., supporting updated labeling and/or indications for int…